Company profile
ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (9)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Nogapendekin Alfa Inbakicept | approved | — | 47 | approved |
| ALDOXORUBICIN | phase2 | — | 3 | no active trials |
| ETBX-011 | phase2 | — | 17 | terminated, withdrawn |
| ETBX-021 | phase2 | — | 9 | terminated, withdrawn |
| ETBX-051 | phase2 | — | 17 | terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (79)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06022224 | phase2_3 | terminated | 2020-12-09 | 2022-06-23 | ImmunityBio, Inc. | A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL |
| NCT06710288 | phase2 | recruiting | 2024-11-06 | 2027-05-01 | ImmunityBio, Inc. | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer |
| NCT07556757 | phase1 | terminated | 2025-04-11 | 2026-07-01 | ImmunityBio, Inc. | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia |
| NCT02138734 | phase1_2 | active_not_recruiting | 2014-07-21 | 2026-09-30 | ImmunityBio, Inc. | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer |
| NCT04927884 | phase1_2 | terminated | 2021-09-08 | 2022-09-13 | ImmunityBio, Inc. | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761336 | BLA | Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. | ||||
Loading… | ||||||